QUALITY OF LIFE OF PATIENTS WITH OVARIAN CANCER OF THE THIRD STAGE USING DIFFERENTIATED TREATMENT
The aim of this research was to assess the quality of life in patients with stage III ovarian cancer during the treatment period, depending on the applied therapeutic approaches.
A comparative analysis of the results of treatment of 350 patients with adenocarcinoma of the ovaries of III-IV stage, which have undergone suboptimal or non-optimal cytomelective surgery, was conducted. To assess the quality of life and to examine the relationship between changes in physical health and quality of life, patients in both groups were asked to complete the questionnaires EORTC QLQ-C30 and SF-36. According to the questionnaire of the EORTC QLQ-C30, the indicators of physical activity, the ability to do everyday affairs, were higher in the second group of patients who received differentiated treatment. The indicator of "social functioning" was also higher in the II group of patients. When evaluating the patients' liver on the scale of the questionnaire SF-36, it was found that the positive effect of differentiated therapy is maintained for 3 years. Life quality is an important criterion for evaluating the results of antitumor therapy, and when it is continuously monitored in patients with ovarian cancer the safety of treatment for patients could be improved, including at an advanced stage
Hvastunov, R. A., Stolorenko, V. V., Lyutaya, E. D., Devyatchenko, T. F., Egin, E. I. (2004). Diagnosticheskie algoritmyi kompleksnogo monitoringa pri spetsialnom lechenii rasprostranennogo raka yaichnikov. Sovremennaya onkologiya, 6 (1), 11–16.
Tyulyandin, S. A. (1999). Vyibor himioterapii pervoy linii u bolnyih rasprostranennyim rakom yaichnikov. Voprosyi onkologii, 4, 350–354.
Shinde, S., Wanger, T., Novotny, P., Grudem, M., Jatoi, A. (2015). Disease-free ovarian cancer patients report severe pain and fatigue over time: prospective quality of life assessment in a consecutive series. European Journal of Gynaecological Oncology, 36 (2), 155–160.
Doll, K. M., Pinheiro, L. C., Reeve, B. B. (2017). Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study. Gynecologic Oncology, 144 (2), 348–353. doi: 10.1016/j.ygyno.2016.12.005
Di Maio, M., Perrone, F. (2016). Lessons from clinical trials on quality-of-life assessment in ovarian cancer trials. Annals of Oncology, 27 (6), 961–962. doi: 10.1093/annonc/mdw153
Ustun, T. B., Chatterji, S., Kostanjsek, N., Rehm, J., Kennedy, C., Epping-Jordan, J. et. al. (2010). Developing the World Health Organization Disability Assessment Schedule 2.0. Bulletin of the World Health Organization, 88 (11), 815–823. doi: 10.2471/blt.09.067231
Zhurman, V. N., Eliseeva, E. V., Gulevich, A. P., Volkov, M. V. (2016). Otsenka kachestva zhizni bolnyih rakom yaichnikov I-III stadii po obschemu oprosniku EQ-5D i spetsialnomu oprosniku EORTC QLQ-C30. Kachestvennaya klinicheskaya praktika, 2, 46–51.
Zhou, Y., Irwin, M. L., Ferrucci, L. M., McCorkle, R., Ercolano, E. A., Li, F. et. al. (2016). Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors – I. Gynecologic Oncology, 141 (3), 543–549. doi: 10.1016/j.ygyno.2016.04.006
Halafyan, A. A. (2008). Statistica 6. Statisticheskiy analiz dannyih. Moscow: OOO «Binom-Press», 512.
Ahmed-Lecheheb, D., Joly, F. (2016). Ovarian cancer survivors’ quality of life: a systematic review. Journal of Cancer Survivorship, 10 (5), 789–801. doi: 10.1007/s11764-016-0525-8
Thaker, P. H., Sereika, S. M., Arida, J., Edwards, R. P., Donovan, H. (2015). A comparison of monthly symptom reports for older (≥ 70 years) versus younger (< 70 years) women with recurrent ovarian cancer over 1 year. Journal of Clinical Oncology, 33(29), 85. doi: 10.1200/jco.2015.33.29_suppl.85
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M., Vergote, I. B., Rustin, G. J. S. et. al. (2014). 885pdhealth-related quality of life (hrqol) during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (psr soc) and a brca mutation (brcam). Annals of Oncology, 25 (4), 308–309. doi: 10.1093/annonc/mdu338.11
Phippen, N. T., Secord, A. A., Wolf, S., Samsa, G., Davidson, B., Abernethy, A. P. et. al. (2017). Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecologic Oncology. doi: 10.1016/j.ygyno.2017.07.121
Colombo, N., Lorusso, D., Scollo, P. (2017). Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future. International Journal of Gynecological Cancer, 27 (6), 1134–1140. doi: 10.1097/igc.0000000000001023
Roncolato, F. T., Gibbs, E., Lee, C. K., Asher, R., Davies, L. C., Gebski, V. J. et. al. (2017). Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Annals of Oncology, 28 (8), 1849–1855. doi: 10.1093/annonc/mdx229
Lutgendorf, S. K., Shinn, E., Carter, J., Leighton, S., Baggerly, K., Guindani, M. et. al. (2017). Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecologic Oncology, 146 (1), 101–108. doi: 10.1016/j.ygyno.2017.05.008
Bhugwandass, C. S., Pijnenborg, J. M. A., Pijlman, B., Ezendam, N. P. M. (2016). Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry. Current Oncology, 23 (6), 556–562. doi: 10.3747/co.23.3243
King, M. T., Stockler, M. R., Butow, P., O’Connell, R., Voysey, M., Oza, A. M. et. al. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns. International Journal of Gynecological Cancer, 24 (5), 865–873. doi: 10.1097/igc.0000000000000167
Lawrie, T. A., Winter-Roach, B. A., Heus, P., Kitchener, H. C. (2015). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.cd004706.pub5
Dubinina, V. H., Rybin, A. I. (2016). Yakist zhyttia khvorykh na rak yaiechnykiv yak indykator funktsionalnoi otsinky efektyvnosti adiuvantnoi platynovoi khimioterapii. Visnyk morfolohii, 22 (2), 328–331.
Copyright (c) 2017 Andriy Rybin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.